Lantheus Holdings, Inc
LNTH
$99.95
-0.24%
Lantheus Holdings, Inc. is a radiopharmaceutical-focused healthcare company that develops, manufactures, and commercializes diagnostic and therapeutic agents used across the cancer care continuum, organized into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships segments. Its flagship franchise centers on PYLARIFY, a leading PSMA PET imaging agent for prostate cancer, complemented by DEFINITY for echocardiography and a growing therapeutic pipeline, positioning the company as a pure-play leader in nuclear medicine and molecular imaging rather than a diversified big-pharma participant. The current investor narrative is dominated by the debate over whether PYLARIFY's growth can be sustained against emerging competitive PSMA imaging agents, even as the company invests heavily in therapeutic radiopharmaceuticals and reported a return to positive net income in the June 2026 quarter. Recent analyst actions have turned cautious, with Truist, TD Cowen, and William Blair all downgrading to Hold/Market Perform ratings in early August 2026, reflecting tempered near-term expectations despite the stock's strong longer-term performance.…
LNTH
Lantheus Holdings, Inc
$99.95
Investment Opinion: Should I buy LNTH Today?
We assign a Hold rating on LNTH, reflecting a balanced view of deep value offset by significant growth and competitive risks. The analyst consensus average target of $107.74 implies 7.8% upside, but the recent downgrades to Hold/Market Perform by multiple firms suggest limited near-term catalysts. The core thesis is that the stock is cheap on forward earnings (15.67x) but faces a 'show-me' story on revenue reacceleration.
The supporting evidence for a Hold is mixed: revenue growth has stalled at 2.68% year-over-year, but free cash flow is robust at $509.73 million TTM, and the balance sheet is strong with $595.02 million in cash and a current ratio of 2.70. Profitability remains solid with a 19.33% net margin and 21.43% ROE, though margins are compressing. The forward PE of 15.67x is below the specialty pharma peer range of 15-25x, suggesting the market is pricing in pessimism that may be overdone if PYLARIFY stabilizes.
The biggest risks that could invalidate the thesis are: (1) accelerated competitive erosion of PYLARIFY, which accounts for 62% of revenue; (2) further margin compression if R&D spending continues to rise without revenue growth; and (3) a breakdown below the $99-$100 support level, which could trigger a retest of the 52-week low of $49.67. We would upgrade to Buy if revenue growth reaccelerates above 5% and PYLARIFY shows stable market share, or downgrade to Sell if revenue declines and the forward PE fails to hold above 12x. Relative to its history, the stock is undervalued on a PS basis (2.91x vs. historical 9-20x), but the low multiple may be justified by structural growth concerns.
Sign up to view all
LNTH 12-Month Price Forecast
LNTH presents a classic value-versus-growth dilemma: the stock is cheap on forward earnings (15.67x) and generates substantial free cash flow, but revenue growth has stalled and competitive risks are rising. The analyst community has turned cautious, with multiple downgrades in August 2026, yet even the lowest target ($102.50) is above the current price. We would upgrade to bullish if PYLARIFY revenue reaccelerates or pipeline catalysts emerge, and downgrade to bearish if revenue declines or margins compress further. The risk/reward is balanced, with limited downside to the 52-week low but also limited near-term upside without a growth catalyst.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Lantheus Holdings, Inc's 12-month outlook, with a consensus price target around $107.74 and implied upside of +7.8% versus the current price.
Average Target
$107.74
0 analysts
Implied Upside
+7.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $115
Analyst target range
Eight analysts cover LNTH, with a consensus average target price of $107.74, implying approximately 7.8% upside from the current price of $99.96. The recommendation field is listed as "none," but the institutional ratings history reveals a distinctly cautious tone: Truist Securities downgraded to Hold from Buy on August 4, 2026, TD Cowen moved to Hold from Buy on August 3, 2026, and William Blair shifted to Market Perform from Outperform on August 3, 2026, while CJS Securities also downgraded to Market Perform from Market Outperform on August 4. The consensus therefore leans neutral-to-cautiously-bullish, with the average target offering modest upside but the recent wave of downgrades signaling that sell-side conviction has weakened materially.
The target range spans from a low of $102.50 to a high of $115.00, a relatively tight spread of $12.50, or about 12% of the midpoint, which signals stronger analyst conviction about the company's fair value than a wide dispersion would. Notably, even the low target of $102.50 sits above the current price, implying that analysts collectively see the stock as modestly undervalued, with the high target of $115.00 assuming successful pipeline execution, stabilization of PYLARIFY revenue, and potential multiple expansion toward the upper end of the historical range. The tight clustering of targets combined with the recent downgrades suggests analysts are recalibrating toward a "show-me" stance, where upside depends on tangible evidence of revenue reacceleration or therapeutic pipeline catalysts rather than multiple expansion alone.
Bulls vs Bears: LNTH Investment Factors
The bear case currently holds stronger evidence due to the sharp revenue deceleration to 2.68% growth, margin compression, and a wave of analyst downgrades. However, the bull case is underpinned by deep value (forward PE of 15.67x), robust free cash flow of $509.73 million, and a fortress balance sheet with $595 million in cash. The single most important tension is whether PYLARIFY's 62% revenue concentration can stabilize against competitive PSMA imaging entrants; a resolution either way would dramatically alter the thesis. If PYLARIFY growth reaccelerates or the therapeutic pipeline delivers, the stock could re-rate; if competition erodes the franchise, the low multiple could prove justified.
Bullish
- Deep Value on Forward Earnings: LNTH trades at a forward PE of just 15.67x versus a trailing PE of 19.23x, a discount to the specialty pharma peer range of 15-25x. With estimated EPS of $9.87, the market is pricing in significant skepticism that may prove overdone.
- Robust Free Cash Flow Generation: The company generated $509.73 million in trailing twelve-month free cash flow, with $211.77 million in Q2 2026 alone. This self-funding capacity supports pipeline investment and potential buybacks without balance sheet strain.
- Fortress Balance Sheet: A current ratio of 2.70, debt-to-equity of just 0.57, and $595.02 million in cash provide ample liquidity. Interest coverage of 20.39x and a cash flow-to-debt ratio of 0.35 signal minimal financial risk.
- Analyst Targets Imply Upside: The consensus average target of $107.74 offers 7.8% upside, and even the lowest target of $102.50 sits above the current price. The tight $12.50 target range signals high conviction in fair value.
Bearish
- Revenue Growth Has Stalled: Q2 2026 revenue grew just 2.68% year-over-year to $388.18 million, a sharp deceleration from prior double-digit growth. Sequential revenue has been essentially flat for four quarters, ranging from $377 million to $407 million.
- Extreme Product Concentration Risk: PYLARIFY alone generated $240.37 million, or 62% of total revenue, making the entire investment thesis dependent on a single prostate cancer imaging franchise. Any competitive erosion would disproportionately impact results.
- Margin Compression Evident: Gross margin fell to 62.30% in Q2 2026 from 63.75% a year earlier, while net margin declined to 19.33% from 20.83%. Rising R&D spending, which hit $38.20 million in Q2 2026, continues to pressure profitability.
- Analyst Downgrade Wave: Truist, TD Cowen, William Blair, and CJS Securities all downgraded LNTH to Hold/Market Perform in early August 2026. This coordinated caution reflects weakening sell-side conviction in near-term growth.
LNTH Technical Analysis
LNTH is in a sustained uptrend on a trailing twelve-month basis, with the shares up 89.71% over the past year versus a 15.01% gain for SPY, a relative strength advantage of 74.70 percentage points. The current price of $99.96 sits at approximately 80.6% of the 52-week range, calculated from a 52-week low of $49.67 to a 52-week high of $111.86, meaning the stock is trading in the upper portion of its annual band but has not reclaimed its highs. This positioning suggests a stock that has already priced in a substantial recovery but is now consolidating rather than pressing to new highs, leaving room for either a breakout continuation or a deeper mean-reversion pullback.
Short-term momentum has clearly decelerated and now diverges from the longer-term trend: the stock is down 0.84% over the past month and down 9.04% over the past three months, even as it remains up 31.35% over six months and 48.60% year-to-date. This divergence is confirmed by relative strength figures, with LNTH underperforming SPY by 1.43 percentage points over one month and by 12.38 percentage points over three months, signaling that the market's enthusiasm has cooled materially since the spring. The recent price action has been remarkably flat, with the stock oscillating in a tight band around $100 from late July through early October 2026, a consolidation pattern that typically resolves in the direction of the prevailing trend but can also mark distribution if volume expands on downside breaks.
Key technical levels are well defined: support rests near the 52-week low of $49.67, with a more immediate psychological and structural floor around the $99-$100 zone where the stock has repeatedly found buyers, while resistance sits at the 52-week high of $111.86. A decisive breakout above $111.86 would signal renewed institutional accumulation and likely open the door to new all-time highs, whereas a breakdown below $99 would risk a retest of the mid-$90s and potentially the $75-$80 area that served as the launchpad for the spring rally. The stock's beta of -0.034 is a critical risk-management consideration, indicating essentially no correlation to the broader market and implying that LNTH's volatility is driven almost entirely by company-specific and sector-specific catalysts rather than macro beta, which makes position sizing based on index-relative risk misleading.
Beta
-0.06
-0.06x market volatility
Max Drawdown
-12.8%
Largest decline past year
52-Week Range
$50-$112
Price range past year
Annual Return
+89.7%
Cumulative gain past year
| Period | LNTH Return | S&P 500 |
|---|---|---|
| 1m | -1.0% | +1.2% |
| 3m | -6.4% | +4.5% |
| 6m | +22.7% | +14.6% |
| 1y | +89.7% | +16.0% |
| ytd | +48.6% | +14.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LNTH Fundamental Analysis
Revenue growth has decelerated sharply to a near-standstill, with Q2 2026 revenue of $388.18 million representing just 2.68% year-over-year growth versus $378.05 million in Q2 2025, a marked slowdown from the double-digit expansion the company enjoyed in prior cycles. The multi-quarter trend shows revenue essentially flat, moving from $384.01 million in Q3 2025 to $406.79 million in Q4 2025, $377.33 million in Q1 2026, and $388.18 million in Q2 2026, a pattern of stagnation rather than acceleration. Segment data reveals the concentration risk clearly: PYLARIFY (Oncology) generated $240.37 million and DEFINITY (Cardiology) $88.28 million, meaning the prostate cancer imaging franchise accounts for roughly 62% of total revenue, so any competitive erosion in PSMA PET imaging would disproportionately drag overall growth.
Profitability remains solid but is compressing from peak levels, with Q2 2026 net income of $75.03 million on a 19.33% net margin and a gross margin of 62.30%, down from the 63.75% gross margin recorded in Q2 2025. The quarterly progression shows volatility: net income swung from $118.42 million in Q1 2026 (31.38% net margin) to $75.03 million in Q2 2026, while Q3 2025 net income was only $27.77 million (7.23% margin) and Q4 2024 was a loss of $11.79 million. Operating margin of 20.16% and EBITDA of $115.44 million in Q2 2026 (29.74% EBITDA margin) indicate the core business is profitable, but the compression from the 34.61% net margin in Q3 2024 highlights margin pressure that likely reflects rising R&D spending, which reached $38.20 million in Q2 2026, and competitive pricing dynamics.
Balance sheet health is a clear strength, with a current ratio of 2.70, a debt-to-equity ratio of 0.57, and $595.02 million in cash at the end of Q2 2026 against modest debt levels. Free cash flow is robust at $509.73 million on a trailing twelve-month basis, with Q2 2026 free cash flow of $211.77 million and operating cash flow of $217.33 million, demonstrating the company's ability to fund its pipeline internally without external financing. Return on equity of 21.43% and ROA of 8.38% confirm efficient capital deployment, while the interest coverage ratio of 20.39x and cash flow-to-debt ratio of 0.35 provide ample cushion, though the company's aggressive $100 million share repurchases in Q3 and Q4 2025 signal management's confidence in intrinsic value even as growth slows.
Quarterly Revenue
$388180000.0B
2026-06
Revenue YoY Growth
+2.7%
YoY Comparison
Gross Margin
62.3%
Latest Quarter
Free Cash Flow
$509732000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LNTH Overvalued?
Because Lantheus is profitable with trailing net income of $75.03 million in the most recent quarter and positive EPS of $0.052, the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 19.23x versus a forward PE of 15.67x, and the gap between these two figures implies the market expects meaningful earnings growth over the next twelve months, consistent with analyst estimated EPS of $9.87 for the forward period. The forward PE of 15.67x is notably low in absolute terms for a healthcare company with a 21.43% ROE, suggesting the market is pricing in either decelerating growth or competitive risk that may prove overdone if PYLARIFY stabilizes.
On a peer-relative basis, the valuation picture is mixed: the PS ratio of 2.91x and EV/Sales of 4.20x appear reasonable for a specialty radiopharmaceutical company, while the PB ratio of 4.12x and EV/EBITDA of 11.77x sit in a middle range. The PEG ratio of -0.82 is negative and therefore not meaningful as a growth-adjusted signal, reflecting the distortion from the low trailing EPS base rather than a genuine valuation anomaly. Compared to the broader Drug Manufacturers - Specialty & Generic industry, where profitable names often trade at 15-25x earnings, LNTH's forward PE of 15.67x sits at the lower end, implying a discount that may reflect the market's skepticism about the sustainability of PYLARIFY's franchise amid competitive PSMA imaging entrants.
Historically, LNTH's valuation has compressed dramatically: the PE ratio stood at 31.27x in Q3 2025, 20.29x in Q4 2025, 10.36x in Q1 2026, and 24.12x in Q2 2026, while the PS ratio has fallen from 20.13x in Q3 2024 to 2.91x currently, a massive de-rating. The current PS of 2.91x is near the bottom of the stock's multi-year range, which historically ranged from roughly 9x to 20x, suggesting the market has repriced the company from a high-growth premium multiple to a mature, cash-generative valuation. This compression could represent a value opportunity if growth reaccelerates, but it could equally signal structural concerns about the durability of the PYLARIFY franchise that justify a permanently lower multiple.
PE
19.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant given the revenue stagnation. Q2 2026 revenue grew only 2.68% year-over-year, and the company's 62% revenue concentration in PYLARIFY means any competitive loss would have an outsized impact. Margin compression is evident, with gross margin falling to 62.30% from 63.75% and net margin declining to 19.33% from 20.83% a year earlier. While the balance sheet is strong with $595.02 million in cash and a current ratio of 2.70, the company's aggressive R&D spending ($38.20 million in Q2 2026) and potential need for pipeline investment could pressure future cash flows if revenue doesn't reaccelerate.
Market and competitive risks are heightened by the stock's premium valuation relative to its growth. Although the forward PE of 15.67x is low in absolute terms, the PS ratio of 2.91x, while down from historical levels of 9-20x, still reflects expectations of a turnaround. The beta of -0.034 indicates virtually no correlation to the broader market, meaning LNTH is highly susceptible to company-specific news and sector rotation. The recent downgrades by Truist, TD Cowen, William Blair, and CJS Securities highlight growing skepticism about PYLARIFY's durability against emerging PSMA imaging agents. Additionally, the lack of dividend yield (0%) and payout ratio (0) means total return depends entirely on price appreciation.
In a worst-case scenario, competitive erosion of PYLARIFY could lead to revenue declines, margin compression, and a sharp multiple contraction. If PYLARIFY loses market share faster than expected, the stock could retest its 52-week low of $49.67, representing a 50.3% downside from the current price of $99.96. Even a moderate bear case, such as revenue growth turning negative and the forward PE compressing to 12x, could push the stock to the mid-$70s, a 25% decline. The analyst low target of $102.50 provides little downside protection, as it assumes stabilization; a more severe scenario could see the stock fall to the $75-$80 range that served as the launchpad for the spring rally.
FAQ
The most severe risk is competitive erosion of PYLARIFY, which accounts for 62% of revenue, as new PSMA imaging agents enter the market. Financial risks include margin compression, with gross margin falling to 62.30% from 63.75%, and rising R&D spending that could pressure cash flow if revenue doesn't grow. Market risks include the stock's low beta (-0.034) meaning it is highly sensitive to company-specific news, and the recent analyst downgrades signal waning confidence. Finally, a breakdown below the $99-$100 support level could trigger a sharp decline toward the 52-week low of $49.67, representing 50% downside.
Our 12-month forecast has a base case (55% probability) targeting $102.50-$115.00, assuming revenue stabilizes and the stock trades near the analyst average of $107.74. The bull case (25% probability) targets $115-$125 if pipeline catalysts emerge and PYLARIFY reaccelerates. The bear case (20% probability) targets $49.67-$75 if competitive erosion accelerates. The most likely scenario is the base case, hinging on PYLARIFY maintaining its market share and margins stabilizing around 62%.
LNTH appears undervalued on a forward PE basis at 15.67x, which is below the specialty pharma peer range of 15-25x and the stock's own trailing PE of 19.23x. The PS ratio of 2.91x is near the bottom of its historical range of 9-20x, indicating a significant de-rating. However, the low multiple may reflect legitimate concerns about PYLARIFY's growth sustainability, given the 2.68% revenue growth. The market is pricing in stagnation, so if growth reaccelerates, the stock could re-rate higher; if competition intensifies, the discount may persist.
LNTH is a good buy only for value-oriented investors with a high risk tolerance, given the 7.8% upside to the analyst average target of $107.74 and the deep forward PE of 15.67x. However, the 2.68% revenue growth and 62% concentration in PYLARIFY present significant risks that could lead to a retest of the 52-week low of $49.67. The recent downgrades by multiple analysts suggest near-term caution, but the strong free cash flow of $509.73 million and $595 million cash balance provide a margin of safety. For those willing to hold through volatility, the risk/reward is balanced, but it is not a compelling buy for growth investors.
LNTH is better suited for long-term investment (minimum 2-3 years) given the binary nature of its pipeline catalysts and the need for PYLARIFY stabilization. The stock's beta of -0.034 means it does not track the market, so short-term trading based on macro trends is ineffective. The lack of dividend (0% yield) means returns depend entirely on price appreciation, which may take time to materialize. Short-term traders could exploit volatility around earnings, but the risk of a sharp decline to the 52-week low of $49.67 makes it unsuitable for low-risk, short-term positions.